What good are whizzy new drugs if the world can’t afford them?
Bringing gene therapies and obesity drugs to the masses will require financial innovation too, says Steven Pearson
IN RECENT YEARS biotechnology and pharmaceutical science have produced quantum leaps that both offer great opportunity and pose great risk. Gene therapies for rare conditions and obesity drugs for larger segments of society could transform health for the better. But for that to happen, policymakers and the companies behind these new treatments need to adapt quickly to the daunting cost challenges associated with them.
More from By Invitation
Keep the code behind AI open, say two entrepreneurs
Martin Casado and Ion Stoica argue that open-source models will power innovation without compromising security
Not all AI models should be freely available, argues a legal scholar
The more capable they are, the greater the risk of catastrophe, reckons Lawrence Lessig
Neil Kinnock on the post-war-like challenges facing Keir Starmer
A lack of social cohesion compared with 1945 makes them even more daunting, says the former Labour leader and Starmer confidant
A prominent donor on why the Democrats shouldn’t anoint Kamala Harris
A competition to replace Joe Biden would better serve the party, and the country, argues Joe Ravitch
Halt the Olympics to save the planet, pleads a sports historian
David Goldblatt thinks pausing the spectacle might jolt the world into grasping the severity of the climate challenge
Rachael “Raygun” Gunn on the new sport that will invigorate the Olympics
The Australian breaker hopes we’ll all soon be talking about B-Girls, B-Boys and double airflares